Learn about Inhaled Biologics at SMI London Conference

We are thrilled to announce that Professor Daniela Traini, Non-Executive Director and Scientific Co-Founder of Ab Initio Pharma, will be presenting at SMI London Conference on the latest advancements in soft mist inhaler biologicals. This event, hosted by SMI London, promises to showcase cutting-edge research and development in respiratory drug delivery.

Professor Traini's presentation will delve into innovative approaches and technologies in the formulation and delivery of biologics via soft mist inhalers, emphasizing the impact on patient outcomes and therapeutic efficacy.

Did You Know?

At Ab Initio Pharma, we specialize in developing inhaled biologics, including proteins, peptides, RNA, and oligonucleotides. Our expertise in GMP manufacturing and our commitment to environmental sustainability ensure that we deliver high-quality, safe, and effective therapies for clinical trials and beyond.

For more information on our capabilities and to explore potential collaborations, please visit Ab Initio Pharma and reach out to our team. We look forward to advancing the future of inhaled therapies together.